NMT bounces ahead on demand from Roche
This article was originally published in Clinica
Livingston, Scotland device producer NMT Group beat analysts' sales expectations in the first four months of 2003, said CEO Roy Smith. Speaking at the company's AGM on May 6, he said that demand from trading partner Roche for the company's first-generation safety syringe had propelled the sales growth. Higher demand had been matched by higher production at the Livingston manufacturing plant, and with this had come reduced unit costs. The company continues to seek additional first-generation syringe business partners.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.